MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-23-2023
Zymeworks P/E Ratio 2011-2026 | ZYME
Annual P/E Ratio Zymeworks
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.99 | -13.2 | -11.9 | -11.7 | -15.5 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.99 | -15.5 | -11.2 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 21.91 | 2.34 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-4.91 | $ 0.94 | 5.23 % | $ 6.91 M | China |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
14.1 | $ 22.7 | 3.37 % | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-0.544 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-0.136 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
6.11 | $ 102.78 | -2.55 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-0.0467 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-5.58 | $ 4.16 | 1.84 % | $ 445 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-213 | $ 23.75 | 2.09 % | $ 3.02 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.45 | 0.35 % | $ 386 M | Britain |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
706 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 3.03 | 4.12 % | $ 4.99 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
3.63 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
bluebird bio
BLUE
|
-0.316 | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
-0.0166 | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
-2.54 | $ 1.76 | 2.03 % | $ 118 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-0.22 | $ 1.11 | 4.25 % | $ 13.6 M | USA |
 |
Cabaletta Bio
CABA
|
-1.69 | $ 3.02 | 2.43 % | $ 303 M | USA |
 |
Cara Therapeutics
CARA
|
-0.457 | - | -3.03 % | $ 260 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-29.7 | - | - | $ 35.4 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-32.5 | - | - | $ 3.45 B | USA |